• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Europace: Boston Scientific touts new safety results for its lead-free S-ICD

Europace: Boston Scientific touts new safety results for its lead-free S-ICD

June 25, 2013 By Arezu Sarvestani

Boston Scientific logo

Boston Scientific (NYSE:BSX) touted the results of a comparative analysis of patients treated with the subcutaneous implantable defibrillator, reporting that its lead-free ICD may be safer for patients.

The lead-free S-ICD system, which uses electrodes implanted beneath the skin rather than leads connected to the heart, resulted in fewer major lead and surgical complications when compared with traditional transvenous ICDs, according to an analysis presented this week at the 2013 Europace meeting of the European Heart Rhythm Assn.

"The benefits of the S-ICD System leaving the heart and vasculature untouched are becoming more evident," study presenter Dr. Jens Brock Johansen said in prepared remarks. "These are very exciting outcomes, since implanting an S-ICD System is relatively new compared with implanting transvenous ICDs. Having supportive outcomes in the acute phase is incredibly important and I am optimistic about the potential benefits the S-ICD System may have in the long term."

Researchers compared outcomes with the S-ICD to outcomes in patients treated with both single and dual chamber transvenous implantable defibrillators. The S-ICD study reported a 1.4% rate of "major lead complications," compared with 4.3% in single chamber TV ICDs and 5.4% for dual chamber TV ICDs. Major lead complications were defined as lead-related re-intervention, pneumothorax, cardiac perforation, according to a press release.

The S-ICD also resulted in a 7.9% rate of surgical complications, compared with 11.5% for the single and dual chamber TV ICDs. There was no significant difference in the rate of pocket revision or major hematoma among the devices, Boston Scientific reported.

The data came from Boston Scientific’s EFFORTLESS S-ICD international post-market registry as well as from a the Danish ICD registry of single and dual-chamber implantations. More than 1,000 patients were analyzed in total, according to a company statement.

The findings were more good news for Boston Scientific’s 1-of-a-kind device, which was also recently the subject of guidance from the U.K.’s National Institute for Health & Care Excellence.

"The NICE interventional procedure guidance on the insertion of the S-ICD System is a welcome step in the development of this new therapy," U.K. cardiologist Dr. Andrew Grace said on behalf of Boston Scientific. "The guidance complements the growing evidence supporting its application in a larger patient pool."

Boston Scientific acquired the S-ICD technology last year with the acquisition of Cameron Health, a deal valued at up to $1.35 billion. The device has been on the European market since July 2009 and was approved by U.S. healthcare regulators in September 2012.

Filed Under: News Well Tagged With: Boston Scientific, Cameron Health Inc., Cardiac Rhythm Management, Clinical Trials, Conference coverage

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy